Viva BioInnovator (VBI) successfully held 1st Demo Day
On 11 June 2020, Viva BioInnovator (VBI) successfully held its 1st Demo Day e-congress. Among nearly 50 incubation portfolio companies from the VBI platform, 8 startup companies attended this event, namely Forkhead Bio Therapeutics, DTx Pharma, Epican Technology, Acelink Therapeutics, TechnoDerma, VersaPeutics, Arthrosi Therapeutics and Totient, covering numerous fields including hereditary nephropathy, gout, diabetes, dermatological diseases, spinal cord injuries and early diagnosis of oncology. Over 200 domestic and overseas top-tier investors, representatives of investment institutions, R&D representatives of pharmaceutical companies, etc. participated in the event and conducted in-depth communication with company founders in an interactive way online.
Dr. David Xu, the Chief Business Officer of Viva Biotech, said, 'Leveraging Viva Biotech's world-leading structure-based drug discovery platform, innovative equity-for-service (EFS) business model as well as a novel drug R&D partner team of nearly 30 experts, VBI's innovative drug investment has reached a certain scale. Innovation in biopharmaceutical field requires cooperation between various parties. As an open platform focusing on biopharmaceutical innovation, VBI upholds a compatible attitude and is willing to enter into in-depth cooperation and communication with VC/PE, biotech companies, colleges, research institutions and other complementary CRO service institutions, to help companies grow fast, together establishing a biopharmaceutical innovation ecosystem.'
Apart from the conventional guests speech session, investor representatives from Sequoia Capital, Kaitai Capital, WisdoMont Asset Management, LH Ventures, etc., who had invested in those invited incubated companies, were also invited to VBI Demo Day. The previous investors shared their investment logics in aspects of technical path, market prospects and competitive strengths of each project.
VBI has been maintaining close cooperation with global renowned institutes, incubation centers, domestic and overseas investment institutions and biopharmaceutical industry conferences. It reviews approximately 600 to 1,000 projects every year with a strict reviewing scheme, under which the pass rate is only 5%. As of the end of 2019, VBI has already incubated 46 projects in total. It will continue adhering to the concept of scale-up investment with an estimated total number of incubated companies of over 100 in the next year. During the previous year, VBI's incubated projects made good progress with R&D and financing. Among which, companies including QurALis Corporation, QureBio, DTx Pharma, VivaVision, etc. successfully completed financing, and Anji Pharmaceuticals, Dogma Therapeutics, ABM Therapeutics and Arthrosi Therapeutics made steady progress with clinical trials.
In the future, VBI will continue organizing Demo Day events regularly, aiming to provide founders of the incubated companies with a better platform for financing, communication and exhibition, and further enhance the innovative biopharmaceutical investment ecosystem which centers on Viva Biotech and creating more values for companies on the platform, endeavoring to realize a win-win circumstance.
